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Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst
formation and variable renal function decline that frequently leads to end-stage renal failure. With the
advent of renoprotective treatment, there is renewed interest in noninvasive biomarkers to help identify
patients at risk of rapid disease progression at early stages. Urinary tissue inhibitor of metalloproteinases-
2 (TIMP-2) and insulin-like growth factor–binding protein 7 (IGFBP7) have been validated as early markers
of acute kidney injury. Because these markers are associated with tubular damage, we studied the per-
formance of both markers in a cohort with chronic tubular pathology. We investigated whether these
biomarkers may be useful to evaluate disease severity in ADPKD.
Methods: In a cross-sectional analysis, we measured TIMP-2 and IGFBP7 in stored spot urine samples of pa-
tients with ADPKD with various stages of chronic kidney disease (CKD) and healthy controls by enzyme-linked
immunosorbent assay. Renal function was estimated using the CKD–Epidemiology Collaboration equation.
Patients were stratiﬁed according to the Kidney Disease Outcomes Quality Initiative classiﬁcation for CKD. In a
subset of patients, total kidney volume (TKV; using magnetic resonance imaging [MRI]) was measured.
Results: In 296 patients with ADPKD (45.5  11.5 years, 51.0% female, serum creatinine 106 [85–147] mmol/l),
urine levels of TIMP-2 and IGFBP7 were not increased or tended to be lower as compared with 71 healthy
controls (46.5 18.5 years, 72.6% female). The levels did not differ across CKD stages, which remained so after
correcting for urine creatinine or osmolality, and for age, sex, and urine protein in multivariable analyses.
Conclusions: Urinary levels of TIMP-2 and IGFBP7 were not higher in patients with ADPKD, and did not
correlate with disease severity.
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A utosomal dominant polycystic kidney disease(ADPKD) is the most common inherited kidney
disease with a prevalence of 1:2500 to 1:3300.1 The dis-
ease is caused by mutations in the PKD1 (85% of cases) or
PKD2 gene (15% of cases) and characterized by pro-
gressive development of multiple cysts in both kidneys
and various extrarenal manifestations, such as liver cysts
and intracranial aneurysms.2 The course of disease pro-
gression is highly variable. ADPKD frequently leads to
end-stage renal disease between the fourth and seventh
decades of life.3 In clinical practice, measurement of
serum creatinine and estimated glomerular ﬁltration rate
(eGFR) is used to monitor kidney function and progres-
sion of disease. However, progressive cyst formation and
loss of nephrons precedes a decline in eGFR.4 Therefore,
in the earlier stages of disease, serum creatinine is a poor
predictor of disease progression in ADPKD.
With the advent of treatment that slows the rate of
disease progression, there is renewed interest in alterna-
tive, noninvasive biomarkers to identify patients at high
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risk for rapid progression in the early stage of disease and
to evaluate therapeutic efﬁcacy. Although several markers
have been studied in ADPKD, including neutrophil
gelatinase-associated lipocalin, kidney injury molecule-1,
interleukin-18, monocyte chemotactic protein-1, and
copeptin (reviewed in Park and Ahn5), their predictive
value is limited. Total kidney volume (TKV) adjusted for
height (htTKV) and age determined by computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) is more
accurate in predicting renal disease progression in patients
with typical morphology of ADPKD.6,7 However, in many
hospitals the use of a CT orMRI scan tomeasure TKV is not
yet standard practice due to limitations pertaining to time
and cost. Furthermore, follow-up TKVmeasurements seem
to be less suitable for the evaluation of long-term treatment
effects.8
Urinary tissue inhibitor of metalloproteinases-2 (TIMP-
2) and insulin-like growth factor–binding protein 7
(IGFBP7) have been validated as early biomarkers of acute
kidney injury (AKI). In AKI, these markers outperform
other urinary markers.9 In chronic kidney disease (CKD),
data regarding TIMP-2 and IGFBP7 are sparse. The exact
role of TIMP-2 and IGFBP7 in renal physiology remains to
be determined. Abundant secretion of IGFBP7 in prox-
imal tubular cells and distal tubular cells and TIMP-2 in
distal tubular cells is associatedwith early tubular damage
in an ischemia-reperfusion injury model.10Whether these
tubular damage markers also play a role in chronic renal
dysfunction is unclear. Because the pathophysiology of
ADPKD involves tubular dysfunction, measurement of
urinary TIMP-2 and IGFBP7 in patients with CKD due to
ADPKD might be of interest.
We performed a cross-sectional analysis of a well-
characterized cohort of patients with ADPKD with
different stages of CKD to determine whether these
markers correlated with disease severity. Disease severity
was categorized according to eGFR and htTKV. We hy-
pothesized that in ADPKD, progressive cyst growth and
compression of surrounding tissue cause a snowball ef-
fect with multiple repetitive acute ischemic events,
which may result in an increase in urinary TIMP-2.
Because tubular injury is not limited to distal tubules





Baseline spot urine samples from patients with ADPKD
were obtained from 4 distinct cohorts: (i) second
morning fasting samples from patients taking part in a
multicenter trial, the DIPAK 1 study (Developing In-
terventions to halt Progression of Autosomal dominant
polycystic Kidney disease) (n ¼ 137). Participants in
this trial were included from July 2012 through March
2015, were 18 to 60 years of age and had an eGFR be-
tween 30 and 60 ml/min per 1.73 m2. Their htTKV was
measured at baseline.11 (ii) In addition, second morning
fasting samples were obtained from adult patients (age
19–74 years, eGFR 13–134 ml/min per 1.73m2) taking
part in the DIPAK 2 study (2013–2015, n ¼ 189), a
multicenter observational study investigating renal
disease progression (change in eGFR and htTKV). (iii)
Nonfasting samples were also obtained from a single-
center observational study conducted between 2007
and 2009 (n¼ 82). In this cohort (age 19–67 years, eGFR
11–136 ml/min per 1.73 m2), Meijer et al.12 previously
analyzed other urinary biomarkers. (iv) Nonfasting
samples were collected from patients (age 19–77 years,
eGFR 8–120 ml/min per 1.73 m2) participating in the
centralized Dutch Parelsnoer Institute/CuraRata bio-
bank initiative (2010, n ¼ 56). Subjects included in
these studies were diagnosed with ADPKD based on the
modiﬁed Ravine criteria.13
Healthy Controls
Stored nonfasting spot urine samples were used as
controls. These samples were obtained from the
following sources: (i) baseline samples from a single-
center study on healthy volunteers (age 18–81 years)
taking part in a vaccination study (n¼ 60) conducted in
2008.14 (ii) Healthy people (age 32–75 years, eGFR 71–
114 ml/min per 1.73 m2) who came to our center for
medical examination before donating a kidney (2014,
n ¼ 17). (iii) Healthy employees (age 33–59 years) of the
outpatient clinic at our center who donated samples
anonymously (2015, n ¼ 17).
The relevant national and institutional ethics com-
mittees approved all procedures in all studies and
subjects gave informed consent before donating sam-
ples. Consent included storage and use in future studies
such as ours.
Sample Collection, Storage, and Measurement
Aliquots were stored at 80C and thawed before
analysis. The samples underwent 2 freeze/thaw cycles
before analysis. Urine concentrations of TIMP-2 and
IGFBP7 were determined using sandwich enzyme-
linked immunosorbent assay (DTM200; R&D systems,
Minneapolis, MN, for TIMP-2 and EK0991; Boster
Biological Technology, Pleasanton, CA for IGFBP7) ac-
cording to the manufacturer’s instructions. Sample di-
lutions used were checked to be within the linear
range, and the same lot numbers (P115276 for TIMP-2
and 637121261219 for IGFBP7) were used throughout
the entire study. Two internal quality control (QC)
samples (QC1 and QC2), consisting of pooled urine,
were analyzed in triplicate on each sample plate to
CLINICAL RESEARCH SEI Dekker et al.: Urinary TIMP-2 and IGFBP7 in Patients With ADPKD
834 Kidney International Reports (2019) 4, 833–841
assess the stability of the assay. For TIMP-2, total
analytical imprecision, expressed as CV%, was 2.8% at
183 pmol/l for QC1 (n ¼ 21) and 3.6% at 238 pmol/l for
QC2 (n ¼ 21). For IGFBP7 total imprecision during the
study was 11.8% at 945 pmol/l for QC1 (n ¼ 17) and
16.1% at 2237 pmol/l for QC2 (n ¼ 18). The product of
these 2 markers (TIMP-2  IGFBP7) is the concentra-
tion of TIMP-2 (pmol/l) multiplied by the concentra-
tion of IGFBP7 (pmol/l) divided by 1000 ([pmol/l2]/
1000).
Urine osmolality was determined using the Osmo-
Station (ARKRAY Inc., Kyoto, Japan). Two internal
QC samples (Lyphocheck Quantitative Urine Control
Normal and Abnormal; Bio-Rad Laboratories, Irvine,
CA) were used. Here the mean and CV values ob-
tained were 320 mOsm/kg and 0.5% for the normal
QC (n ¼ 12) and 868 mOsm/kg and 0.9% for the
abnormal QC (n ¼ 11). The urinary concentrations of
total protein, albumin, and creatinine were measured
on a Modular P800 (Roche Diagnostics, Basel,
Switzerland) according to instructions from the
manufacturer.
Because urine osmolality is associated with disease
severity in patients with ADPKD, biomarker concentra-
tions might be affected by dilution of urine in the tubule.
This makes urine osmolality a potential confounder.
Therefore, TIMP-2 and IGFBP7 were normalized to urine
osmolality and expressed as a ratio of the biomarker
divided by osmolality. Both markers were also corrected
for urine creatinine and expressed as the biomarker
divided by creatinine.
Renal function was derived from serum creatinine
based eGFR applying the CKD–Epidemiology Collabo-
ration equation15 and using an isotope dilution mass
spectrometry (IDMS)–standardized, selective enzymatic
creatinine method. We stratiﬁed patients with ADPKD
according to the CKD classiﬁcation, based on 5 cate-
gories of eGFR, proposed by the Kidney Disease Out-
comes Quality Initiative.16 Stages 4 and 5 were
combined into 1 group (CKD 4–5). CKD 1: $ 90 ml/min
per 1.73 m2; CKD 2: 60 to 89 ml/min per 1.73 m2; CKD 3:
30 to 59 ml/min per 1.73 m2; CKD 4–5: <30 ml/min per
1.73 m2.
MRI data of the DIPAK 1 study were obtained at the
same time point as the urine samples and were used to
measure TKV in patients with ADPKD. Abdominal MRI
was performed using a standardized imaging procedure
without the administration of i.v. contrast. The protocol
includes T2-weighted single-shot fast gradient spin-echo
sequence with fat saturation.11 TKV was analyzed by
means of a validated stereology technique.17,18 An online
imaging calculator was used to estimate htTKV and to
stratify patients into 5 subclasses (1A–1E by htTKV and
age) according to the Mayo classiﬁcation.19 This model
predicts disease progression in patients with typical
ADPKD.6
Statistical Analysis
Continuous variables with normal distribution are
expressed as mean  SD and nonparametric variables are
summarized by median and interquartile range (IQR).
Categorical data are given as proportions. Normality of
variable distribution was tested by the Kolmogorov-
Smirnov test. The independent t test and one-way
ANOVA were used for analyses when data were nor-
mally distributed. In case of skewed distribution of data,
Mann-Whitney U test and Kruskal-Wallis test were used
to compare continuous variables. Multivariable regres-
sion analyses were used to investigate the associations
between the urinary biomarkers and eGFR or htTKV,
with sequential adjustment for potential confounding
factors (age, sex, urine creatinine, urine osmolality, and
urine protein concentration). For all analyses, 2-sided P
values < 0.05 were considered to indicate statistical
signiﬁcance. Analyses were performed using SPSS,
version 23.0 (SPSS Inc., Chicago, IL) and GraphPad (La
Jolla, CA) Prism, version 7.0.2.
RESULTS
Study Cohort
A total of 464 patients with ADPKD and 94 controls
were identiﬁed. The study population consisted of 296
patients with ADPKD (mean age 45.5  11.5 years,
51.0% female) and 71 controls (mean age 46.5  18.5
years, 72.6% female) for whom sufﬁcient urine material
was available for analyses. As expected, age, body mass
index, and renal function signiﬁcantly differed across
the CKD stages in patients with ADPKD, as indicated in
Table 1.
Correlation of Urinary TIMP-2 and IGFBP7 with
ADPKD and Stages of CKD
Levels of TIMP-2 (P ¼ 0.24) and IGFBP7 (P ¼ 0.40)
were comparable between patients with ADPKD and
healthy controls, as was the product of both markers
(TIMP-2xIGFBP7, P ¼ 0.33). Normalized to urine
creatinine, both TIMP-2 (P ¼ 0.02) and IGFBP7 levels
(P ¼ 0.03) were signiﬁcantly lower in patients with
ADPKD as compared with controls (Table 2, Figures 1a
and 2a). Urine protein levels were higher in patients
with ADPKD than in controls (median 0.07 [IQR 0.04–
0.12] g/l vs. 0.05 [IQR 0.04–0.08] g/l, respectively, P ¼
0.003), as shown in Table 2.
In patients with ADPKD, there were no differences
in uncorrected urinary TIMP-2 (P ¼ 0.73), IGFBP7
(P ¼ 0.50) and TIMP-2xIGFBP7 levels (P ¼ 0.75) be-
tween the various CKD stages. Similar results were
found after correcting TIMP-2 and IGFBP7 for urine
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creatinine (TIMP-2/Creat, P ¼ 0.10; IGFBP7/Creat, P ¼
0.07) (Table 2, Figures 1b and 2b). Osmolality was
lower in patients with ADPKD with later-stage CKD
(P ¼ 0.03, across CKD stages) (Figure 3). Median levels
of urine osmolality ranged from 475 (IQR 231–614)
mOsm/kg in patients with preserved renal function to
336 (IQR 307–397) mOsm/kg in patients with CKD stage
4–5. Seeing that urine is more diluted in later-stage CKD,
we corrected for this effect on the urine biomarker level
(TIMP-2/Osm and IGFBP7/Osm). Figure 4 shows that
after correcting for osmolality, neither TIMP-2
(Figure 4a) nor IGFBP7 (Figure 4b) differed across the 4
CKD stages, P ¼ 0.11 and P ¼ 0.57, respectively.
In addition to the comparison of biomarkers across the
CKD stages, we analyzed the association of both urinary
markers with eGFR as a continuous variable. In a
multivariable regression model with only conventional
markers, age, urine osmolality, and urine protein were
signiﬁcantly associated with eGFR (r2¼ 0.48, P< 0.001).
Adding urinary TIMP-2 (r2¼ 0.48) or IGFBP7 (r2¼ 0.49)
or TIMP-2  IGFBP7 (r2 ¼ 0.49) did not improve the
model (P > 0.05 for the addition of these biomarkers).
Correlation of Urinary TIMP-2 and IGFBP7 With
htTKV
For 95 patients with ADPKD, measurements of htTKV
were available. This subgroup was stratiﬁed into 5
subclasses (1A–1E) according to the Mayo classiﬁcation
system, which is based on htTKV and age. Patients who
were classiﬁed as atypical (Mayo class 2, n ¼ 7) were
excluded from analyses. In this subgroup, patients had
a median eGFR of 52.1 (IQR 41.4–60.7) ml/min per 1.73
m2. There was a large spread in htTKV, with values
ranging from 314 ml to 4481 ml (median 1044 ml/m).
Osmolality-corrected TIMP-2 (P ¼ 0.16) and IGFBP7
(P ¼ 0.41), and creatinine-corrected TIMP-2 (P ¼ 0.09)
and IGFBP7 (P ¼ 0.50) did not differ across the Mayo
subclasses 1A-B (n ¼ 15), 1C (n ¼ 39), 1D (n ¼ 23), or 1E
(n ¼ 18) (Figure 5a and b).
Furthermore, a multivariable linear regression model
including htTKV as continuous variable and all potential
confounders (age, sex, eGFR, urine creatinine, urine
osmolality, and urine protein) showed no association
between htTKV and TIMP-2 or IGFBP7 or their product
(r2¼ 0.13, r2¼ 0.13, and r2¼ 0.12, respectively, all P>
0.05). This also applied for the model built only on the
clinical risk markers (r2 ¼ 0.11, P ¼ 0.09).
Correlation of Urinary TIMP-2 and IGFBP7 With
Albuminuria
In addition, we analyzed the association of biomarker
levels and albuminuria, seeing that this may inﬂuence
biomarker levels. Patients were stratiﬁed according to
their urine albumin-creatinine ratio into 3 categories of
albuminuria: <3 mg/mmol (n ¼ 112), 3–30 mg/mmol
(n ¼ 95), and >30 mg/mmol (n ¼ 8). Creatinine-corrected
IGFBP7 (P ¼ 0.26), and osmolality-corrected IGFBP7
(P ¼ 0.92) were comparable across all groups. Patients
with albuminuria had higher levels of urinary TIMP-2
levels corrected for creatinine (P < 0.001) or osmolality
(P ¼ 0.004). The median TIMP-2/Osm was 0.2 (IQR 0.1–
0.3) pmol/mOsm for patients with a normal to mildly
Table 1. Patient characteristics
Variable ADPKD
Stages of CKD
1 2 3 4--5
n 296 60 95 112 29
Female sex, n (%) 151 (51.0) 30 (50.0) 56 (58.9) 50 (44.6) 15 (51.7)
Mean age, yr (SD) 45.5 (11.5) 33.1 (9.4) 44.5 (8.9)a 51.5 (9.3)a 51.0 (8.7)a
Median BMI, kg/m2 (IQR) 25.8 (23.1–28.9) 22.5 (20.9–27.5) 26.1 (23.1–29.3)a 26.3 (24.2–29.0)a 26.3 (23.9–31.5)a
Median serum creatinine, mmol/l (IQR) 106.0 (85.3–146.8) 73.5 (67.3–85.0) 93.0 (84.0–106.0)a 140.0 (119.0–159.8)a 229.0 (200.0–304.0)a
Median eGFR, ml/min per 1.73 m2 (IQR) 60.7 (42.9–84.7) 102.0 (92.9–110.6) 70.4 (63.7–81.8)a 45.9 (37.7–53.4)a 21.6 (18.5–28.1)a
ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated GFR; IQR, interquartile range.
aP < 0.005 versus stage 1.
Table 2. Urinary biomarker levels in controls and patients with ADPKD
Variable Controls ADPKD
Stages of CKD
1 2 3 4--5
n 71 296 60 95 112 29
TIMP-2/Creat, pmol/mmol 15 (10–20) 12 (8 -18)a 10 (3–20) 13 (7–17) 11 (8–17) 14 (10–22)
IGFBP7/Creat, pmol/mmol 121 (80–164) 103 (84–130)a 104 (81–145) 104 (86–145) 113 (77–122) 122 (91–148)
TIMP-2  IGFBP7, pmol/l2/1000 48 (15–214) 48 (10–124) 34 (3–254) 60 (10–167) 50 (18–99) 38 (21–80)
Creatinine, mmol/l 5289 (3166–10410) 5898 (3350–8826) 5394 (2410–11658) 6235 (3393–9728) 6091 (4075–8451) 5061 (3671–6408)
Total protein, g/l 0.05 (0.04–0.08) 0.07 (0.04–0.12)a 0.07 (0.04–0.11) 0.06 (0.04–0.10) 0.07 (0.04–0.12) 0.08 (0.04–0.22)
ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; Creat, creatinine; TIMP-2, tissue inhibitor of metalloproteinase-2; IGFBP7, insulin-like growth
factor–binding protein 7.
Data are given as median (interquartile range).
aP < 0.05 versus controls.
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increased albumin-creatinine ratio, 0.2 (IQR 0.2–0.4)
pmol/mOsm for those with moderate albuminuria, and
0.4 (IQR 0.2–0.5) pmol/mOsm in patients with severe
albuminuria (P ¼ 0.004, across groups).
Correlation of Urinary TIMP-2 and IGFBP7 With
Types of Gene Mutation
Genetic analysis was available for 196 patients and
showed pathogenic mutations in the PKD1 gene (n ¼
132, 67.3%), PKD2 gene (n ¼ 39, 19.9%), in both genes
(n ¼ 9, 4.6%), or in neither of these 2 genes (n ¼ 16,
8.2%). In this subgroup, urine biomarker levels did not
differ between patients with a PKD1 or PKD2 mutation
(P ¼ 0.30 for TIMP-2, and P ¼ 0.76 for IGFBP7).
Creatinine-corrected TIMP-2 (P ¼ 0.23) and IGFBP7
(P ¼ 0.93), and osmolality-corrected TIMP-2 (P ¼ 0.15)
and IGFBP7 (P ¼ 0.51) levels were also comparable
between the groups. In patients with a PKD1 mutation,
the median TIMP-2/Osm level was 0.2 (IQR 0.1–0.3)
pmol/mOsm, and the median IGFBP7/Osm level was 1.7
(1.3–2.2) pmol/mOsm. In patients with a PKD2 muta-
tion the median TIMP-2/Osm level was 0.2 (IQR 0.1–
0.3) pmol/mOsm, and the median IGFBP7/Osm level 1.7
(1.3–2.2) pmol/mOsm. In addition, no differences were
found between the 2 genetic mutation groups in the
association of both biomarkers with eGFR in multi-
variable regression analyses adjusted for all potential
confounders (P for interaction ¼ 0.35 for TIMP2, and P
for interaction ¼ 0.09 for IGFBP7).
DISCUSSION
This study evaluated urinary TIMP-2 and IGFBP7 as
potential biomarkers for disease severity in patients
Figure 1. Urine tissue inhibitor of metalloproteinase-2 (TIMP-2)/
creatinine (Creat) in autosomal dominant polycystic kidney disease
(ADPKD) according to chronic kidney disease (CKD) stage and
healthy controls (HCs). TIMP-2/Creat levels were signiﬁcantly lower
in patients with ADPKD as compared with HCs (a, *P ¼ 0.02)
and not significantly different across CKD stages (b, P ¼ 0.10).
Boxplots represent median, interquartile ranges, and their 5–95
percentiles.
Figure 2. Urine insulin-like growth factor–binding protein 7
(IGFBP7)/creatinine (Creat) in autosomal dominant polycystic
kidney disease (ADPKD) according to chronic kidney disease (CKD)
stage and healthy controls (HCs). IGFBP7/Creat levels were
signiﬁcantly lower in patients with ADPKD as compared with HCs
(a, *P ¼ 0.03) and not significantly different across CKD stages (b,
P ¼ 0.07). Boxplots represent median, interquartile ranges, and
their 5–95 percentiles.
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with ADPKD. Levels of TIMP-2 and IGFBP7, corrected
for urine creatinine or osmolality, remained stable
regardless of renal dysfunction or kidney volume.
The advent of renoprotective treatment requires
early risk stratiﬁcation in ADPKD. Because the disease
course of ADPKD is highly variable, it is important to
select patients at high risk of rapid disease progression
for timely treatment, and to identify low-risk patients
to avoid unnecessary treatment. Conventional markers
for disease severity in ADPKD including glomerular
ﬁltration rate indexed for age and htTKV both have
their limitations. Therefore, there is an unmet clinical
need for alternative markers that associate with disease
severity and progression in the early stages of ADPKD.
Urinary TIMP-2 and IGFBP7 have been validated
as biomarkers to predict the onset of AKI.9 A urine
test, based on the product of TIMP-2 and IGFBP7, has
been approved by the US Food and Drug Adminis-
tration for predicting early-stage AKI. Urinary TIMP-
2 has also separately shown to be of predictive value
in renal transplant recipients for the occurrence and
duration of graft dysfunction.20 Because ADPKD is
characterized by tubular dysfunction, we measured
these urinary tubular damage markers in a CKD
cohort with ADPKD and different disease stages. The
advantage of urinary markers is that their measure-
ment is relatively easy and inexpensive. Because we
were particularly interested in the distal tubular
marker TIMP-2, we measured this marker separately
in addition to IGFBP7 and their product. We hy-
pothesized that urinary TIMP-2 levels increased in
patients with ADPKD in response to multiple repet-
itive acute ischemic events due to cyst growth and
compression of surrounding tissue. In contrast to our
hypothesis, normalized levels of TIMP-2 as well as
IGFBP7 were lower in patients with ADPKD as
compared with healthy controls, and no differences
between the rate of disease severity (eGFR, htTKV,
type of gene mutation) were found in ADPKD. This
makes it less likely that these biomarkers can predict
progression of disease. However, this point remains
uncertain as the design of our study was cross-
sectional and this would require a follow-up study
with sequential measurements of biomarkers and
eGFR over time.
The mechanisms underlying increased urinary
TIMP-2 and IGFBP7 were recently determined in mice
with acute renal injury. In AKI, elevated urinary
excretion is caused by increased glomerular perme-
ability for these proteins, impaired proximal tubular
reabsorption, and release of these proteins from tubular
Figure 3. Urine osmolality in autosomal dominant polycystic
kidney disease according to chronic kidney disease (CKD) stage.
Lower urine osmolality levels were found in more advanced CKD
stages (P ¼ 0.03, across CKD stages). *P < 0.05 versus stage 1
(Mann-Whitney U test). Boxplots represent median, interquartile
ranges, and their 5–95 percentiles.
Figure 4. Urine tissue inhibitor of metaproteinase-2 (TIMP-2)/
osmolality (Osm) and urine insulin-like growth factor–binding
protein 7 (IGFBP7)/Osm in autosomal dominant polycystic kidney
disease according to chronic kidney disease (CKD) stage. TIMP-2/
Osm (a, P ¼ 0.11) and IGFBP7/Osm (b, P ¼ 0.57) did not differ
significantly across CKD stages. Boxplots represent median,
interquartile ranges, and their 5–95 percentiles.
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cells.21 A number of reasons may explain the ﬁndings
in our study. The lower biomarker levels in ADPKD as
compared with controls may be explained by an
impaired glomerular ﬁltration rate. As ADPKD pro-
gresses, lower ﬁltration may be offset by impaired
proximal tubular reabsorption and increased release of
these proteins from tubular cells. The net-result is that
there is no signiﬁcant change in these biomarkers as
ADPKD progresses. In an ischemia-reperfusion injury
model secretion of IGFBP7 and TIMP-2 in tubular cells
is suppressed for 24 hours, followed by abundant
secretion after 6 hours of reperfusion with normalized
secretion after 24 hours of reperfusion.10 In ADPKD,
the injury is of a different kind and the intensity may
be too limited compared with AKI to cause an increase
in these markers. Furthermore, in ADPKD, the type of
injury may differ in that it is irreversible, with ﬁbrosis
in more advanced stages of ADPKD. Last, the injury
may be intermittent, in which case an increase in
biomarker levels may elude detection.
Our data are in line with the study by Kashani
et al.,9 which focused on AKI, but also included some
patients with CKD (n ¼ 65). In the graphs provided in
that article, the product of urinary TIMP-2 and
IGFBP7 did not differ between patients with CKD and
controls. Another small study investigated urinary
IGFBP7 in type 2 diabetic patients (n ¼ 46) (mean
eGFR 74.9  23.6 ml/min per 1.73 m2). In contrast to
our study, urinary levels of IGFBP7 were signiﬁcantly
higher in patients with macroalbuminuria than in
those with normoalbuminuria or microalbuminuria,
and correlated with eGFR.22 This may be related to the
speciﬁc pathophysiology of diabetic nephropathy,
which is characterized by glomerular dysfunction.
The study has a number of strengths. First, the study
population was of sufﬁcient size and was well distrib-
uted across the stages of CKD to allow a ﬁrm conclusion.
Second, the biomarkers were analyzed in relation to the
conventional markers of disease severity, assessed as
eGFR, htTKV, albuminuria, and type of gene mutation.
In the earlier stages of disease, htTKV is a better marker
of progression of ADPKD than eGFR. Third, TIMP-2 and
IGFBP7 levels were corrected for urinary creatinine as
well as urinary osmolality. Most studies have normalized
urinary biomarkers to creatinine only, which is inﬂu-
enced by muscle mass and variability in ﬁltration and
secretion.23 Our data conﬁrmed the well-known fact that
urine osmolality is reduced in patients with ADPKD with
more advanced CKD. However, also after correcting for
urinary osmolality biomarker levels were similar at
different stages of CKD, in accordance to the results after
correcting for urinary creatinine.
This study also has limitations. First, the urine
samples were stored at 80C for prolonged periods
and had gone through 2 freeze-thaw cycles. Schuh
et al.24 evaluated the effects of repeated freeze-thaw
cycles and prolonged storage for 5 years on urinary
neutrophil gelatinase-associated lipocalin, kidney
injury molecule-1, and interleukin-18. There was a
minimal decrease of 1% to 3% from baseline values
after 3 freeze-thaw cycles and 80C storage for 5
years.24 Such differences are not clinically relevant.
There are no data published so far regarding long-term
storage of urinary TIMP-2 and IGFBP7. In our study,
we did not ﬁnd an association between storage time
and biomarker levels (data not shown). Second, healthy
control samples were obtained from various sources.
For some controls, actual data on kidney function were
Figure 5. Urine tissue inhibitor of metaproteinase-2 (TIMP-2)/
osmolality (Osm) and urine insulin-like growth factor–binding
protein 7 (IGFBP7)/Osm in autosomal dominant polycystic kidney
disease according to total kidney volume. TIMP-2/Osm (P ¼ 0.16)
and IGFBP7/Osm (P ¼ 0.41) did not differ across strata for total
kidney volume. Kidney volume was classified according to the
Mayo classification system, based on age and height-adjusted total
kidney volume. Boxplots represent median, interquartile ranges,
and their 5–95 percentiles.
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missing, but they all were considered to have normal
renal function based on their medical history. The aim
was to investigate urinary markers to monitor disease
severity in patients with ADPKD and not necessarily to
differentiate patients from controls. Therefore, the
focus was on the group of patients with ADPKD, for
which data on eGFR were complete. Last, htTKV was
not available for a substantial proportion of patients,
which reduces the power of the analysis to detect
differences. Nevertheless, the subgroup was of sufﬁ-
cient size to draw a ﬁrm conclusion.
In conclusion, in patients with ADPKD, we did not
ﬁnd differences in urinary TIMP-2 and IGFBP7 levels
according to disease severity including eGFR, htTKV,
and/or type of genetic mutation.
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